In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aimmune Therapeutics, Inc.

https://www.aimmune.com/

Latest From Aimmune Therapeutics, Inc.

2021: A Record-Breaking Year For ‘Smart’ Pricing And Access Deals In England

NHS England and Improvement (NHSE&I) agreed 16 pricing and access deals with drug companies in 2021, ten of which can be considered ‘smart.’ The fact that these were achieved against a backdrop of COVID-19 is seen as impressive.

United Kingdom Market Access

German HTA Negative On Benefits Of First Ever Peanut Allergy Treatment

The decision by IQWiG could have an impact on how Palforzia is priced if the findings are upheld.

Health Technology Assessment Market Access

DBV Pulls EU Peanut Allergy Patch Filing To Work On A Stronger Application

Following regulatory setbacks in the US and also now in the EU, DBV Technologies is to conduct a new pivotal trial of a modified version of its peanut allergy patch to support its efforts to win marketing approval.

Drug Review Regulation

England’s NICE Okays First Ever Peanut Allergy Treatment Palforzia

Aimmune Therapeutics secures agreement with NHS for “step change” in treating peanut allergy.

Europe United Kingdom
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Allergen Research Corporation (ARC)
UsernamePublicRestriction

Register